Cargando…
Integrating the Neurobiology of Schizophrenia /
A thorough overview of all neurotransmitters involved in schizophrenia.
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam ; Boston :
Elsevier,
2007.
|
| Colección: | International review of neurobiology ;
v. 78. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo Texto completo |
Tabla de Contenidos:
- Cover
- Copyright Page
- Contents
- Contributors
- Preface
- References
- Chapter 1: Neurobiology of Dopamine in Schizophrenia
- I. Introduction
- II. Dopaminergic System in the Brain
- A. Dopaminergic Projections
- B. Dopaminergic Receptors
- III. Evidence Supporting Alterations of DA Systems in Schizophrenia
- A. Pharmacological Evidence
- B. Postmortem Studies
- C. Imaging Studies
- IV. Conclusions
- References
- Chapter 2: The Dopamine System and the Pathophysiology of Schizophrenia: A Basic Science Perspective
- I. Introduction
- II. Neuroanatomy of DA Systems
- III. DA Neuron Activity and Release
- IV. Cellular Actions of DA
- V. Roles of DA on Cognitive and Affective Functions
- VI. Development and Maturation of the DA System
- VII. DA Deficits in Schizophrenia
- VIII. Conclusions
- References
- Chapter 3: Glutamate and Schizophrenia: Phencyclidine, N-Methyl-D-Aspartate Receptors, and Dopamine-Glutamate Interactions
- I. Introduction
- II. Glutamatergic Physiology
- A. Glutamate-Dopamine Comparisons
- B. Glutamate Receptors
- C. NMDA Receptors
- D. AMPA/Kainate Receptors
- E. Metabotropic Receptors
- III. Glutamatergic Models of Schizophrenia
- A. Symptom Patterns Following NMDA Antagonist Administration
- B. Cognitive Deficits Following NMDA Antagonist Treatment
- C. In Vivo Findings in Schizophrenia Based on Dopamine Receptor Occupancy
- D. Postmortem Findings
- IV. Clinical Studies with NMDA Agonists
- A. NMDA Receptor Glycine-Site Agonists
- B. Glycine Transport Inhibitors
- C. Other Ionotropic Targets
- D. Metabotropic Receptors
- E. Group I Receptors
- F. Group II Metabotropic Agonists
- V. Potential Causes of Glutamatergic Dysfunction in Schizophrenia
- A. Dopamine-Glutamate Interactions
- B. Linkage-Association Studies in Schizophrenia
- C. Environmental and Neurochemical Factors
- VI. Future Research and Treatment Implications
- Acknowledgments
- References
- Chapter 4: Deciphering the Disease Process of Schizophrenia: the. Contribution of Cortical Gaba Neurons
- I. Working Memory Impairments: A Core Feature of Schizophrenia
- II. Working Memory Impairments and Altered GABA Neurotransmission in the DLPFC
- III. Potential Pathogenetic Mechanisms for Cell Type-Specific Alterations in GABA Neurons
- A. Reduced Excitatory Drive via NMDA Receptors
- B. Reduced Neurotrophin Signaling
- IV. Connecting Alterations in PV-Positive Neurons to Working Memory Impairments: Decreased Gamma Band Synchrony in Schizophrenia
- V. Treatment Implications
- Acknowledgments
- References
- Chapter 5: Alterations of Serotonin Transmission in Schizophrenia
- I. Introduction
- II. Alteration of 5-HT Receptors in Schizophrenia
- A. 5-HT Transporters
- B. 5-HT1A Receptors
- C. 5-HT2 Receptors
- D. Other Receptors
- III. Pharmacological Manipulation of 5-HT Transmission in Schizophrenia
- A. 5-HT Precursors
- B. 5-HT Depleting Agents
- C. 5-HT2A Agonism: LSD and "Model.